Affiliation:
1. Focus Technologies, Inc., 1217 KP Hilversum, The Netherlands
2. Focus Technologies, Inc., Herndon, Virginia 20171
3. Focus Technologies, Inc., Franklin, Tennessee, 37064
Abstract
ABSTRACT
The prevalence of antimicrobial resistance among 4,940 U.S. pneumococcal isolates collected during 1999 was as follows: penicillin, 16.2%; amoxicillin-clavulanate, 12.2%; cefuroxime, 28.1%; ceftriaxone, 3.6%; trimethoprim-sulfamethoxazole, 30.3%; azithromycin, 21.4%; levofloxacin, 0.6%; and moxifloxacin, 0.1%. Compared to the previous 1997-1998 study (Jones et al., Antimicrob. Agents Chemother.
44:
2645-2652, 2000), increases were noted for resistance to penicillin (3.7%;
P
< 0.001), amoxicillin-clavulanate (3.9%;
P
< 0.001), cefuroxime (5.7%;
P
< 0.001), azithromycin (2.4%;
P
= 0.014), trimethoprim-sulfamethoxazole (15.4%;
P
< 0.001), and levofloxacin (0.3%;
P
= 0.017). Resistance to ceftriaxone (0.1%;
P
= 0.809) and moxifloxacin (0.03%;
P
= 0.570) decreased. Concurrently, multidrug resistance increased (
P
< 0.001) from 6.3% to 11.3%.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献